<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
	<fontspec id="font6" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font7" size="7" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font8" size="8" family="GillSans" color="#000000"/>
<text top="41" left="55" width="162" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Genetic Vaccines and Therapy 2007, 5 :5<i>Genetic Vaccines and Therapy</i></text>
<text top="41" left="394" width="160" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.gvt-journal.com/content/5/1/5</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t3" reading_order_no="101" segment_no="17" tag_type="text">Page 7 of 9<b>5</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="102" segment_no="18" tag_type="text">(page number not for citation purposes)</text>
<text top="87" left="55" width="241" height="9" font="font4" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="text">negative) and the second twin as the recipient (HIV-posi-</text>
<text top="98" left="55" width="241" height="9" font="font4" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="text">tive). Lymphocytes from the donors were transduced to</text>
<text top="110" left="55" width="241" height="9" font="font4" id="p1_t7" reading_order_no="4" segment_no="2" tag_type="text">express a control gene ( neo gene) or anti-HIV gene(s); a<i>(page number not for citation purposes)</i></text>
<text top="122" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">transdominant mutant Rev protein (TdRev) was used</text>
<text top="134" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="2" tag_type="text">alone or with an anti-sense element directed against the</text>
<text top="145" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="7" segment_no="2" tag_type="text">HIV-1 TAR sequence on the same construct. Polymerase</text>
<text top="157" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="2" tag_type="text">chain reaction demonstrated increased survival of modi-<i>neo </i></text>
<text top="169" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="2" tag_type="text">fied lymphocytes in the initial weeks post-infusion in 9 of</text>
<text top="181" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="2" tag_type="text">10 recipients. In six of six recipients followed for approxi-</text>
<text top="192" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="2" tag_type="text">mately two years, T cells containing anti-HIV genes could</text>
<text top="204" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="2" tag_type="text">be consistently detected and there was preferential sur-</text>
<text top="216" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="2" tag_type="text">vival of modified cells in one patient during a period of</text>
<text top="228" left="55" width="83" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="2" tag_type="text">high HIV load [47].</text>
<text top="251" left="55" width="56" height="10" font="font6" id="p1_t18" reading_order_no="15" segment_no="5" tag_type="title">Conclusion</text>
<text top="263" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="6" tag_type="text">Early promising results on the treatment of adenosine</text>
<text top="275" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="6" tag_type="text">deaminase-severe combined immunodeficiency (ADA-</text>
<text top="286" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="6" tag_type="text">SCID) by using gene therapy in the early 1990s [48] led</text>
<text top="298" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="19" segment_no="6" tag_type="text">the scientific community to apply the same principle to a<a href="">47]</a>.</text>
<text top="310" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="20" segment_no="6" tag_type="text">host of other diseases, including HIV/AIDS. In vitro studies<b>Conclusion</b></text>
<text top="322" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="21" segment_no="6" tag_type="text">quickly demonstrated the feasibility of such approaches</text>
<text top="333" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="6" tag_type="text">and preclinical and clinical trials were started later in the</text>
<text top="345" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="23" segment_no="6" tag_type="text">same decade. However, it was soon realized that a cure for<a href="">48</a>] led</text>
<text top="357" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="24" segment_no="6" tag_type="text">HIV was far from easy. As many studies demonstrated,</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="6" tag_type="text">there were no serious adverse effects of the therapy, but</text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="6" tag_type="text">neither was there any decrease of patients' viral loads.<i>In vitro </i></text>
<text top="392" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="27" segment_no="6" tag_type="text">There was also the problem of transduction efficiency,</text>
<text top="404" left="55" width="241" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="6" tag_type="text">and transduced cells had only transient expression of the</text>
<text top="416" left="55" width="241" height="9" font="font4" id="p1_t32" reading_order_no="29" segment_no="6" tag_type="text">transgene. Moreover, there was no consensus on target</text>
<text top="427" left="55" width="104" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="6" tag_type="text">genes and methodology.</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="8" tag_type="text">Despite some discouraging results from clinical trials,</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="8" tag_type="text">gene therapy for HIV is still a very promising approach.</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t36" reading_order_no="33" segment_no="8" tag_type="text">Scientists are already overcoming the problems of insuffi-</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="8" tag_type="text">cient gene transduction by using novel constructs [49] or</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="8" tag_type="text">by switching to lentiviral-mediated transduction [50,51].</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="8" tag_type="text">The first clinical trial using lentiviral vectors in HIV-posi-</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="8" tag_type="text">tive patients began in 2001, and results will be forthcom-</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="8" tag_type="text">ing [52]. The recent clinical studies by Podsakoff et al . and</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="8" tag_type="text">Morgan et al . in 2005 support the hypothesis that anti-</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="8" tag_type="text">HIV genes confer a survival advantage to modified lym-</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="8" tag_type="text">phocytes [40,47], especially under conditions of high HIV<a href=""> [49]</a> or</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t45" reading_order_no="42" segment_no="8" tag_type="text">titers, thus offering a potential benefit to infected individ-<a href="">tion [50,51].</a></text>
<text top="592" left="55" width="19" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="8" tag_type="text">uals.</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="12" tag_type="text">Other promising strategies for the near future include the</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="12" tag_type="text">use of siRNAs and fusion proteins to deliver these mole-<a href="">g [52]</a>. The recent clinical studies by Podsakoff </text>
<text top="639" left="55" width="242" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="12" tag_type="text">cules [53-55]. Early HIV regulatory genes like tat and rev<i>et al</i></text>
<text top="651" left="55" width="241" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="12" tag_type="text">could be susceptible targets for siRNA because genes</text>
<text top="662" left="55" width="241" height="9" font="font4" id="p1_t51" reading_order_no="48" segment_no="12" tag_type="text">encoding late structural proteins are dependent on Tat</text>
<text top="674" left="55" width="242" height="9" font="font4" id="p1_t52" reading_order_no="49" segment_no="12" tag_type="text">and Rev protein expression [56]. Scherer et al . showed that<i>et al</i></text>
<text top="686" left="55" width="241" height="9" font="font5" id="p1_t53" reading_order_no="50" segment_no="12" tag_type="text">tat - and rev -specific siRNAs were more effective at inhibit-</text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="12" tag_type="text">ing HIV-1 replication than multiple siRNAs targeting env</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="12" tag_type="text">[57]. Other research groups have demonstrated success in<a href="">ocytes [40,47</a>], especially under conditions of high HIV</text>
<text top="721" left="55" width="241" height="9" font="font5" id="p1_t56" reading_order_no="53" segment_no="12" tag_type="text">vitro by targeting Gag or HIV receptors with siRNA</text>
<text top="87" left="313" width="241" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="3" tag_type="text">[58,59]. Song et al . (2005) took advantage of the nucleic</text>
<text top="98" left="313" width="241" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="3" tag_type="text">acid binding properties of protamine and fused it to the</text>
<text top="110" left="313" width="241" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="3" tag_type="text">heavy chain Fab fragment of an anti-HIV Env antibody to</text>
<text top="122" left="313" width="168" height="9" font="font4" id="p1_t60" reading_order_no="57" segment_no="3" tag_type="text">deliver siRNA to HIV-infected cells [54].<a href="">53</a>-<a href="">55</a>]. Early HIV regulatory genes like </text>
<text top="145" left="313" width="241" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="4" tag_type="text">According to von Laer et al . (2006), antiviral genes that<i>tat </i></text>
<text top="157" left="313" width="241" height="9" font="font4" id="p1_t62" reading_order_no="59" segment_no="4" tag_type="text">inhibit the processes of reverse transcription and integra-</text>
<text top="169" left="313" width="241" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="4" tag_type="text">tion potentially offer significant therapeutic benefit [60].<i>rev</i></text>
<text top="181" left="313" width="241" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="4" tag_type="text">They based their prediction on mathematical models,</text>
<text top="192" left="313" width="241" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="4" tag_type="text">which analyzed the effects of genetically modified T cells</text>
<text top="204" left="313" width="241" height="9" font="font4" id="p1_t66" reading_order_no="63" segment_no="4" tag_type="text">on viral replication and T cell kinetics. This strategy could<a href="">ion [56]</a>. Scherer </text>
<text top="216" left="313" width="241" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="4" tag_type="text">include targeting cellular factors involved in these enzy-<i>et al</i></text>
<text top="228" left="313" width="241" height="9" font="font4" id="p1_t68" reading_order_no="65" segment_no="4" tag_type="text">matic processes. Developing siRNAs that target reverse</text>
<text top="239" left="313" width="241" height="9" font="font4" id="p1_t69" reading_order_no="66" segment_no="4" tag_type="text">transcriptase and integrase genes themselves have poten-<i>tat</i></text>
<text top="251" left="313" width="241" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="4" tag_type="text">tial to be effective anti-HIV therapies. Although these</text>
<text top="263" left="313" width="241" height="9" font="font4" id="p1_t71" reading_order_no="68" segment_no="4" tag_type="text">genes code for late protein products, inhibition of these<i>rev</i></text>
<text top="275" left="313" width="241" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="4" tag_type="text">genes could create defective virus particles incapable of</text>
<text top="286" left="313" width="166" height="9" font="font4" id="p1_t73" reading_order_no="70" segment_no="4" tag_type="text">initiating subsequent replication cycles.</text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="7" tag_type="text">While the initial achievements using siRNA against HIV<i>env</i></text>
<text top="322" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="7" tag_type="text">have employed transient expression systems, stable sys-<a href="">[57]. Othe</a>r research groups have demonstrated success </text>
<text top="333" left="313" width="241" height="9" font="font4" id="p1_t76" reading_order_no="73" segment_no="7" tag_type="text">tems have been reported and offer hope for long-term effi-<i>in</i></text>
<text top="345" left="313" width="241" height="9" font="font4" id="p1_t77" reading_order_no="74" segment_no="7" tag_type="text">cacy [30,53,61-65]. The specificity of siRNAs reduces the<i>vitro </i></text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="7" tag_type="text">potential side effects of gene therapy but, on the other</text>
<text top="369" left="313" width="241" height="9" font="font4" id="p1_t79" reading_order_no="76" segment_no="7" tag_type="text">hand, it increases the possibility of making a virus par-<a href="">58,59]</a>. Song </text>
<text top="380" left="313" width="241" height="9" font="font4" id="p1_t80" reading_order_no="77" segment_no="7" tag_type="text">tially or completely resistant to siRNA with the slightest<i>et al</i></text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t81" reading_order_no="78" segment_no="7" tag_type="text">mutation [66-69]. The strategy of simultaneously target-</text>
<text top="404" left="313" width="241" height="9" font="font4" id="p1_t82" reading_order_no="79" segment_no="7" tag_type="text">ing several conserved regions of HIV using multiple differ-</text>
<text top="416" left="313" width="241" height="9" font="font4" id="p1_t83" reading_order_no="80" segment_no="7" tag_type="text">ent siRNAs could potentially overcome this problem of</text>
<text top="427" left="313" width="51" height="9" font="font4" id="p1_t84" reading_order_no="81" segment_no="7" tag_type="text">viral escape.<a href="">ed cells [54</a>].</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="9" tag_type="text">In conclusion, gene therapy is a very attractive method for</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t86" reading_order_no="83" segment_no="9" tag_type="text">treating HIV-positive patients. The approaches under-<i>et al</i></text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t87" reading_order_no="84" segment_no="9" tag_type="text">taken so far have yielded encouraging results from a safety</text>
<text top="486" left="313" width="241" height="9" font="font4" id="p1_t88" reading_order_no="85" segment_no="9" tag_type="text">efficacy standpoint. Future efforts should focus on</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t89" reading_order_no="86" segment_no="9" tag_type="text">improving transduction efficiencies and long-term expres-<a href="">nefit [60</a>].</text>
<text top="510" left="313" width="241" height="9" font="font4" id="p1_t90" reading_order_no="87" segment_no="9" tag_type="text">sion and on optimizing cellular targets in order to achieve</text>
<text top="521" left="313" width="241" height="9" font="font4" id="p1_t91" reading_order_no="88" segment_no="9" tag_type="text">the desired therapeutic benefits, which include decreasing</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t92" reading_order_no="89" segment_no="9" tag_type="text">viral loads, increasing or sustaining high CD4 + T cell</text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t93" reading_order_no="90" segment_no="9" tag_type="text">counts, and improving immune function in HIV-infected</text>
<text top="557" left="313" width="50" height="9" font="font4" id="p1_t94" reading_order_no="91" segment_no="9" tag_type="text">individuals.</text>
<text top="580" left="313" width="103" height="10" font="font6" id="p1_t95" reading_order_no="92" segment_no="10" tag_type="title">Competing interests</text>
<text top="592" left="313" width="241" height="9" font="font4" id="p1_t96" reading_order_no="93" segment_no="11" tag_type="text">The author(s) declare that they have no competing inter-</text>
<text top="604" left="313" width="18" height="9" font="font4" id="p1_t97" reading_order_no="94" segment_no="11" tag_type="text">ests.</text>
<text top="627" left="313" width="114" height="10" font="font6" id="p1_t98" reading_order_no="95" segment_no="13" tag_type="title">Authors' contributions</text>
<text top="639" left="313" width="241" height="9" font="font4" id="p1_t99" reading_order_no="96" segment_no="14" tag_type="text">JGM and DPW produced the manuscript together. Both</text>
<text top="651" left="313" width="204" height="9" font="font4" id="p1_t100" reading_order_no="97" segment_no="14" tag_type="text">authors read and approved the final manuscript.</text>
<text top="674" left="313" width="99" height="10" font="font6" id="p1_t101" reading_order_no="98" segment_no="15" tag_type="title">Acknowledgements</text>
<text top="686" left="313" width="241" height="7" font="font8" id="p1_t102" reading_order_no="99" segment_no="16" tag_type="text">We thank the Microbiology and Immunology M.S. Program of Wright State</text>
<text top="697" left="313" width="238" height="7" font="font8" id="p1_t103" reading_order_no="100" segment_no="16" tag_type="text">University and Public Health Service Grant AI057164 for support of JGM.<a href="">cacy [30</a>,<a href="">53,61-65]. The specifici</a>ty of siRNAs reduces the</text>
</page>
</pdf2xml>
